| Ticker Details |
BioCryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
|
| IPO Date: |
March 4, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.48B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.21 | 3.03%
|
| Avg Daily Range (30 D): |
$0.25 | 2.84%
|
| Avg Daily Range (90 D): |
$0.19 | 2.35%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.61M |
| Avg Daily Volume (30 D): |
5.51M |
| Avg Daily Volume (90 D): |
4.12M |
| Trade Size |
| Avg Trade Size (Sh.): |
177 |
| Avg Trade Size (Sh.) (30 D): |
146 |
| Avg Trade Size (Sh.) (90 D): |
146 |
| Institutional Trades |
| Total Institutional Trades: |
4,199 |
| Avg Institutional Trade: |
$2.29M |
| Avg Institutional Trade (30 D): |
$2.81M |
| Avg Institutional Trade (90 D): |
$2.84M |
| Avg Institutional Trade Volume: |
.28M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.24M |
| Avg Closing Trade (30 D): |
$9.17M |
| Avg Closing Trade (90 D): |
$5.66M |
| Avg Closing Volume: |
394.66K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$1.26
|
$1.17
|
$1.26
|
|
Diluted EPS
|
$1.21
|
$1.13
|
$1.21
|
|
Revenue
|
$874.84M
|
$406.56M
|
$874.84M
|
|
Gross Profit
|
$855.76M
|
$397.03M
|
$855.76M
|
|
Net Income / Loss
|
$263.86M
|
$245.85M
|
$263.86M
|
|
Operating Income / Loss
|
$340.99M
|
$260.39M
|
$340.99M
|
|
Cost of Revenue
|
$19.08M
|
$9.52M
|
$19.08M
|
|
Net Cash Flow
|
$-14.99M
|
$-9.56M
|
$-14.99M
|
|
PE Ratio
|
7.90
|
|
|
|
|
|
